Goldman Sachs Upgrades Genmab A/S (GMAB) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts GMAB Hot Sheet
Price: $55.12 -0.72%
Rating Summary:
12 Buy, 2 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
12 Buy, 2 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Goldman Sachs analyst Rajan Sharma upgraded Genmab A/S (NASDAQ: GMAB) from Neutral to Buy with a price target of $30.50 (from $24.50).
For an analyst ratings summary and ratings history on Genmab A/S click here. For more ratings news on Genmab A/S click here.
Shares of Genmab A/S closed at $27.06 yesterday.
You May Also Be Interested In
- Northland Upgrades Astera Labs (ALAB) to Outperform
- ArcBest Corp (ARCB) PT Lowered to $146 at TD Cowen
- Clear Secure Inc (YOU) PT Raised to $80 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
